| Next 10 |
Ad
MXCT News and Press MaxCyte Inc.
News | MaxCyte Inc. (NASDAQ:MXCT)
-
2023-06-09 17:15:14 ET Gainers: PepGen ( PEPG ) +5% . Caribou Biosciences ( CRBU ) +4% . MaxCyte ( MXCT ) +4% . Noodles & Company ( NDLS ) +3% . Applied Digital ( APLD ) +3% . Losers: Couchbase ( BASE ...
-
2023-05-30 13:38:58 ET Summary Cutting-edge cellular engineering firm MaxCyte (MXCT) has developed a platform which enables modifications to cells. Applications of MaxCyte's cellular engineering platform are far-reaching, such as cell-based therapies, gene editing, and drug discov...
-
2023-05-12 13:39:06 ET MaxCyte, Inc. (MXCT) Q1 2023 Earnings Conference Call May 10, 2023 04:30 PM ET Company Participants Sean Menarguez - Head-Investor Relations Doug Doerfler - President & Chief Executive Officer Douglas Swirsky - Chief Financial Office ...
-
2023-05-10 16:29:01 ET MaxCyte press release ( NASDAQ: MXCT ): Q1 GAAP EPS of -$0.11. Revenue of $8.6M (-25.7% Y/Y). Total cash, cash equivalents and short-term investments were $224.7 million as of March 31, 2023. Gross profit for the first quarter of 2023 was $...
-
ROCKVILLE, Md., May 10, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovati...
-
ROCKVILLE, Md., May 04, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to suppor...
-
ROCKVILLE, Md., April 12, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support innovat...
-
2023-04-12 04:49:05 ET Summary MaxCyte’s flow electroporation technology has made them the industry leader and the best bet for biotech companies that need a partner that specializes in non-viral cell engineering. MaxCyte’s revenue mostly comes from milestone and roy...
-
2023-03-27 17:06:39 ET MaxCyte ( NASDAQ: MXCT ) on Monday said Douglas Swirsky has been appointed chief financial officer, effective immediately. Swirsky, who has over two decades of experience in the healthcare sector, notably served as CEO of Rexahn...
-
ROCKVILLE, Md., March 27, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support i...
Stock Information
MaxCyte Inc. Company Name:
MXCT Stock Symbol:
NASDAQ Market:
Get MXCT Alerts
News, Short Squeeze, Breakout and More Instantly...
Ad
